Back to top
more

Oncternal Therapeutics (ONCT)

(Delayed Data from NSDQ)

$1.50 USD

1.50
72,859

+0.04 (2.74%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $1.50 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 4.62% and 233.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Stevanato Group (STVN) Q2 Earnings Match Estimates

Stevanato (STVN) delivered earnings and revenue surprises of 0% and 1.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of -25.88% and 0.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 1.74% and 223.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy

Oncternal Therapeutics (ONCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oncternal Therapeutics (ONCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Oncternal Therapeutics (ONCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -0.65% and 74.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 92.31% and 77.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Q4 Earnings Lag Estimates

Zoetis (ZTS) delivered earnings and revenue surprises of -6.77% and 1.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 11.76% and 49.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 9.09% and 23.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 4.76% and 1.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?

Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.

United Therapeutics (UTHR) Q1 Earnings Beat Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 11.72% and 1.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals

bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog.

Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates

Earnings and pipeline updates from bluebird bio (BLUE) and Avidity (RNA) are the key highlights for the biotech sector.

Oncternal (ONCT) Down on Restructuring Plan to Extend Runway

Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.

Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -9.52% and 7.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corcept Therapeutics (CORT) Lags Q4 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of -39.13% and 0.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 5.83% and 2%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Reports Q4 Loss, Misses Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.64% and 5.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?